Investigation of de novo mutations in a schizophrenia case-parent trio by induced pluripotent stem cell-based in vitro disease modeling: convergence of schizophrenia- and autism-related cellular phenotypes.


Journal

Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581

Informations de publication

Date de publication:
27 11 2020
Historique:
received: 23 09 2020
accepted: 18 10 2020
entrez: 28 11 2020
pubmed: 29 11 2020
medline: 22 6 2021
Statut: epublish

Résumé

De novo mutations (DNMs) have been implicated in the etiology of schizophrenia (SZ), a chronic debilitating psychiatric disorder characterized by hallucinations, delusions, cognitive dysfunction, and decreased community functioning. Several DNMs have been identified by examining SZ cases and their unaffected parents; however, in most cases, the biological significance of these mutations remains elusive. To overcome this limitation, we have developed an approach of using induced pluripotent stem cell (iPSC) lines from each member of a SZ case-parent trio, in order to investigate the effects of DNMs in cellular progenies of interest, particularly in dentate gyrus neuronal progenitors. We identified a male SZ patient characterized by early disease onset and negative symptoms, who is a carrier of 3 non-synonymous DNMs in genes LRRC7, KHSRP, and KIR2DL1. iPSC lines were generated from his and his parents' peripheral blood mononuclear cells using Sendai virus-based reprogramming and differentiated into neuronal progenitor cells (NPCs) and hippocampal dentate gyrus granule cells. We used RNASeq to explore transcriptomic differences and calcium (Ca NPCs derived from the SZ patient exhibited transcriptomic differences related to Wnt signaling, neuronal differentiation, axonal guidance and synaptic function, and decreased Ca The approach of reprograming case-parent trios represents an opportunity for investigating the molecular effects of disease-causing mutations and comparing these in cell lines with reduced variation in genetic background. Our results are indicative of a partial overlap between schizophrenia and autism-related phenotypes in the investigated family. Our study investigated only one family; therefore, the generalizability of findings is limited. We could not derive iPSCs from two other siblings to test for possible genetic effects in the family that are not driven by DNMs. The transcriptomic and functional assays were limited to the NPC stage, although these variables should also be investigated at the mature neuronal stage.

Sections du résumé

BACKGROUND
De novo mutations (DNMs) have been implicated in the etiology of schizophrenia (SZ), a chronic debilitating psychiatric disorder characterized by hallucinations, delusions, cognitive dysfunction, and decreased community functioning. Several DNMs have been identified by examining SZ cases and their unaffected parents; however, in most cases, the biological significance of these mutations remains elusive. To overcome this limitation, we have developed an approach of using induced pluripotent stem cell (iPSC) lines from each member of a SZ case-parent trio, in order to investigate the effects of DNMs in cellular progenies of interest, particularly in dentate gyrus neuronal progenitors.
METHODS
We identified a male SZ patient characterized by early disease onset and negative symptoms, who is a carrier of 3 non-synonymous DNMs in genes LRRC7, KHSRP, and KIR2DL1. iPSC lines were generated from his and his parents' peripheral blood mononuclear cells using Sendai virus-based reprogramming and differentiated into neuronal progenitor cells (NPCs) and hippocampal dentate gyrus granule cells. We used RNASeq to explore transcriptomic differences and calcium (Ca
RESULTS
NPCs derived from the SZ patient exhibited transcriptomic differences related to Wnt signaling, neuronal differentiation, axonal guidance and synaptic function, and decreased Ca
CONCLUSIONS
The approach of reprograming case-parent trios represents an opportunity for investigating the molecular effects of disease-causing mutations and comparing these in cell lines with reduced variation in genetic background. Our results are indicative of a partial overlap between schizophrenia and autism-related phenotypes in the investigated family.
LIMITATIONS
Our study investigated only one family; therefore, the generalizability of findings is limited. We could not derive iPSCs from two other siblings to test for possible genetic effects in the family that are not driven by DNMs. The transcriptomic and functional assays were limited to the NPC stage, although these variables should also be investigated at the mature neuronal stage.

Identifiants

pubmed: 33246498
doi: 10.1186/s13287-020-01980-5
pii: 10.1186/s13287-020-01980-5
pmc: PMC7694414
doi:

Substances chimiques

KHSRP protein, human 0
LRRC7 protein, human 0
RNA-Binding Proteins 0
Sialoglycoproteins 0
Trans-Activators 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

504

Références

Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 1):2424-37
pubmed: 23628741
Stem Cells Int. 2016;2016:7909176
pubmed: 26839567
Nature. 2014 Feb 13;506(7487):185-90
pubmed: 24463508
Nat Protoc. 2007;2(2):329-33
pubmed: 17406593
Cell Stem Cell. 2014 Jul 3;15(1):79-91
pubmed: 24996170
Mol Psychiatry. 2015 Mar;20(3):361-8
pubmed: 24686136
Schizophr Res. 2019 Aug;210:3-12
pubmed: 30587427
J Comp Neurol. 2008 Apr 20;507(6):1860-70
pubmed: 18271024
Schizophr Bull. 2012 May;38(3):373-6
pubmed: 22461483
Cell Calcium. 2016 Mar;59(2-3):124-34
pubmed: 27020657
Mol Immunol. 2002 May;38(14):1007-21
pubmed: 11955593
Mol Cell Neurosci. 2018 Apr;88:222-230
pubmed: 29425968
Mol Psychiatry. 2011 Jan;16(1):17-25
pubmed: 19786961
Nature. 2014 Feb 13;506(7487):179-84
pubmed: 24463507
PLoS One. 2012;7(6):e39498
pubmed: 22761806
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205
pubmed: 31114916
Trends Biochem Sci. 2018 Sep;43(9):700-713
pubmed: 30057142
Nat Genet. 2019 Oct;51(10):1475-1485
pubmed: 31548722
J Appl Toxicol. 2019 Apr;39(4):556-570
pubmed: 30484873
Mol Psychiatry. 2013 Oct;18(10):1067-76
pubmed: 23732879
Development. 2014 Jun;141(12):2366-75
pubmed: 24917496
Nat Genet. 2011 Sep 18;43(10):969-76
pubmed: 21926974
Nature. 2014 Jan 16;505(7483):361-6
pubmed: 24352232
Wiley Interdiscip Rev RNA. 2016 Mar-Apr;7(2):227-40
pubmed: 26708421
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
Schizophr Res. 2020 Mar;217:26-36
pubmed: 31277978
Nat Neurosci. 2019 Feb;22(2):243-255
pubmed: 30617258
Transl Psychiatry. 2017 Jul 25;7(7):e1179
pubmed: 28742076
Protein Cell. 2020 Jan;11(1):45-59
pubmed: 31134525
Mol Autism. 2020 Apr 16;11(1):26
pubmed: 32299488
NPJ Schizophr. 2017 Oct 2;3(1):35
pubmed: 28970473
Neurosci Biobehav Rev. 2011 Jan;35(3):878-93
pubmed: 20974172
Methods Mol Biol. 2016;1307:141-7
pubmed: 24482125
PLoS One. 2013 Nov 14;8(11):e79255
pubmed: 24244461
JAMA Psychiatry. 2013 Oct;70(10):1107-12
pubmed: 23925787
Semin Cell Dev Biol. 2011 Jun;22(4):416-24
pubmed: 21827867
Mol Genet Genomic Med. 2019 Dec;7(12):e983
pubmed: 31578828
JAMA Psychiatry. 2014 Mar;71(3):334-5
pubmed: 24382673
Mol Autism. 2019 Dec 30;10:51
pubmed: 31893020
Neuropsychopharmacol Hung. 2016 Dec;18(4):188-198
pubmed: 28259862
Nucleic Acids Res. 2020 Jan 8;48(D1):D166-D173
pubmed: 31724725
Cytometry B Clin Cytom. 2014 Sep;86(5):299-310
pubmed: 24729538
Transl Psychiatry. 2019 Oct 3;9(1):244
pubmed: 31582721
Lancet. 2009 Aug 22;374(9690):635-45
pubmed: 19700006
Nature. 2011 May 12;473(7346):221-5
pubmed: 21490598
Stem Cell Reports. 2014 Feb 27;2(3):295-310
pubmed: 24672753
Mol Psychiatry. 2017 Jun;22(6):820-835
pubmed: 27378147
Transl Psychiatry. 2019 Jul 29;9(1):179
pubmed: 31358727

Auteurs

Edit Hathy (E)

National Brain Research Project (NAP) Molecular Psychiatry Research Group, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary.

Eszter Szabó (E)

Molecular Cell Biology Research Group, Institute of Enzymology, Research Center for Natural Sciences, 1117 Magyar tudósok körútja 2, Budapest, Hungary.

Nóra Varga (N)

Molecular Cell Biology Research Group, Institute of Enzymology, Research Center for Natural Sciences, 1117 Magyar tudósok körútja 2, Budapest, Hungary.

Zsuzsa Erdei (Z)

Molecular Cell Biology Research Group, Institute of Enzymology, Research Center for Natural Sciences, 1117 Magyar tudósok körútja 2, Budapest, Hungary.

Csongor Tordai (C)

National Brain Research Project (NAP) Molecular Psychiatry Research Group, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary.

Boróka Czehlár (B)

National Brain Research Project (NAP) Molecular Psychiatry Research Group, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary.

Máté Baradits (M)

National Brain Research Project (NAP) Molecular Psychiatry Research Group, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary.

Bálint Jezsó (B)

Molecular Cell Biology Research Group, Institute of Enzymology, Research Center for Natural Sciences, 1117 Magyar tudósok körútja 2, Budapest, Hungary.

Júlia Koller (J)

Institute of Rare Disorders and Genomic Medicine, Semmelweis University, Budapest, Hungary.

László Nagy (L)

Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Mária Judit Molnár (MJ)

Institute of Rare Disorders and Genomic Medicine, Semmelweis University, Budapest, Hungary.

László Homolya (L)

Molecular Cell Biology Research Group, Institute of Enzymology, Research Center for Natural Sciences, 1117 Magyar tudósok körútja 2, Budapest, Hungary.

Zsófia Nemoda (Z)

Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, Budapest, Hungary.

Ágota Apáti (Á)

Molecular Cell Biology Research Group, Institute of Enzymology, Research Center for Natural Sciences, 1117 Magyar tudósok körútja 2, Budapest, Hungary. apati.agota@ttk.hu.

János M Réthelyi (JM)

National Brain Research Project (NAP) Molecular Psychiatry Research Group, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary. rethelyi.janos@med.semmelweis-univ.hu.
Department of Psychiatry and Psychotherapy, Semmelweis University, Balassa utca 6, Budapest, 1083, Hungary. rethelyi.janos@med.semmelweis-univ.hu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH